TY  - JOUR
AU  - Fogelman, David
AU  - Cubillo, Antonio
AU  - García-Alfonso, Pilar
AU  - Mirón, María Luisa Limón
AU  - Nemunaitis, John
AU  - Flora, Daniel
AU  - Borg, Christophe
AU  - Mineur, Laurent
AU  - Vieitez, Jose M
AU  - Cohn, Allen
AU  - Saylors, Gene
AU  - Assad, Albert
AU  - Switzky, Julie
AU  - Zhou, Li
AU  - Bendell, Johanna
PY  - 2018
DO  - 10.1002/cam4.1703
UR  - http://hdl.handle.net/10668/12853
T2  - Cancer medicine
AB  - The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib,...
LA  - en
KW  - JAK1 protein tyrosine kinase
KW  - JAK2 protein tyrosine kinase
KW  - clinical trial
KW  - colorectal cancer
KW  - inflammation
KW  - ruxolitinib
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Colorectal Neoplasms
KW  - Double-Blind Method
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Janus Kinase 1
KW  - Janus Kinase 2
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Nitriles
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Pyridines
KW  - Pyrimidines
KW  - Recurrence
KW  - Treatment Outcome
TI  - Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
TY  - research article
VL  - 7
ER  -